Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brequinar - Clear Creek Bio

Drug Profile

Brequinar - Clear Creek Bio

Alternative Names: Bipenquinate; Brequinar sodium; DUP 785; NSC 368390; NSC 369390

Latest Information Update: 18 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Clear Creek Bio
  • Class Antineoplastics; Antivirals; Biphenyl compounds; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Phase I/II Acute myeloid leukaemia
  • Discontinued Cancer; Cytomegalovirus infections; Transplant rejection

Most Recent Events

  • 08 Aug 2022 Clear Creek Bio terminates a phase I/II trial in Acute myeloid leukemia in the US due to no efficacy observed (NCT03760666)
  • 22 Jun 2022 Clear Creek Bio terminates the phase II CCBCRISIS04 trial for COVID-2019 infections (Combination therapy) in India (PO), due to low prevalence of COVID-19 in India led to lack of eligible subjects (NCT05166876)
  • 22 Dec 2021 Clear Creek Bio plans a phase II trial CCBCRISIS04 for COVID- 2019 infections (Combination therapy) in India (PO) in December 2021 (NCT05166876)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top